Amylyx Pharmaceuticals, Inc. (AMLX)
33.98
-0.51
(-1.48%)
USD |
NASDAQ |
Sep 03, 16:00
33.98
0.00 (0.00%)
After-Hours: 18:26
Amylyx Pharmaceuticals Research and Development Expense (TTM) : 92.08M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 92.08M |
| March 31, 2026 | 95.43M |
| December 31, 2025 | 89.88M |
| September 30, 2025 | 91.51M |
| June 30, 2025 | 92.79M |
| March 31, 2025 | 88.85M |
| December 31, 2024 | 103.18M |
| September 30, 2024 | 125.06M |
| June 30, 2024 | 133.78M |
| March 31, 2024 | 139.40M |
| Date | Value |
|---|---|
| December 31, 2023 | 127.10M |
| September 30, 2023 | 105.30M |
| June 30, 2023 | 100.31M |
| March 31, 2023 | 95.70M |
| December 31, 2022 | 93.14M |
| September 30, 2022 | 83.73M |
| June 30, 2022 | 71.83M |
| March 31, 2022 | 58.60M |
| December 31, 2021 | 44.02M |
| September 30, 2021 | 35.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc. | 10.82B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| EyePoint, Inc. | 262.73M |
| Bristol Myers Squibb Co. | 9.548B |